- Optimi Health (OPTI) engages U.S. based law firm for patent support
- The firm’s primary focus is on identifying, protecting, licensing, and enforcing intellectual property rights
- Thomas Finetti brings over 16 years of experience in patent law and will be overseeing patent activities.
- The timing of this engagement is strategically important as Optimi prepares to submit a formal application to Health Canada for its phase 1 dosing study
- Optimi Health Corp. (OPTI)is down 3.80 percent and is trading at C$0.76 at12:12 pm ET
Optimi Health Corp. (OPTI) is working with Thomas Finetti, partner at Charney IP Law, to oversee ongoing patent activities.
Based in New Jersey, Charney IP Law concentrates its practise on intellectual property law.
The firm’s primary focus is on identifying, protecting, licensing, and enforcing intellectual property rights.
They provide strategic advice and representation throughout the product life cycle, from research and development of products and services to financing, licensing, and, if necessary, regulatory approval and the enforcement of the rights obtained.
Thomas Finetti brings over 16 years of experience in patent law, combining his strong technical background with his extensive experience in developing effective legal strategies.
Thomas has enjoyed consistent success in growing and leveraging the intellectual property assets of companies of all sizes, including early-stage companies.
Over the course of his career, Thomas has prepared and prosecuted patents in the pharmaceutical, chemical, biotechnology, gene therapy, and diagnostic spaces and ensured his client’s patent portfolios were aligned with their long-term objectives.
He has conducted substantive due diligence activities in connection with the licensing or purchasing of intellectual property assets, including conducting freedom-to-operate and patent validity analyses.
“I’m delighted to have the opportunity to assist the team at Optimi Health,” notes Finetti.
“I look forward to helping grow their patent estate and to support their vision of transforming the treatment of mental health conditions and the broader health and wellness of its customers,” added Finetti.
Building on the previously announced hiring of Justin Kirkland as Chief Science Officer, Kirkland will be pursuing IP and patentable all-natural psilocybin formulations and will work closely with Finetti to beneficially secure these developments for all stakeholders of Optimi.
“I am super excited to continue to work with Thomas,” shares Kirkland.
“I’ve experienced great success with him in the past, taking a concept all the way through two issued patents and a successful exit with the sale of those patents for $10M CAD,” concluded Kirkland.
The timing of this engagement is strategically important as Optimi prepares to submit a formal application to Health Canada for its phase 1 dosing study.
Health Canada has indicated they have no concerns over the plan as proposed, and upon pending acceptance and final approval, Optimi remains on track to begin trials in Q3 of this year.
Phase 2 in Optimi’s clinical research plan will include applications for the utilization of the Company’s proprietary formulations.
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets.
Optimi Health Corp. (OPTI)is down 3.80 percent and is trading at C$0.76 at12:12 pm ET.
